Tuberculosis control in crisis-causes and solutions
- PMID: 31626823
- DOI: 10.1016/j.pbiomolbio.2019.10.001
Tuberculosis control in crisis-causes and solutions
Abstract
Tuberculosis (TB) incidence is projected to decline at too slow a rate to meet the targets set at the UN high level meeting on ending TB, convened in New York in 2018. To understand the causes of the slow progress in TB control, the Bill and Melinda Gates Foundation supported a patient-pathway analysis that identified significant gaps with patients being "lost" at all points along the care cascade. Although each country differed in the reasons for failure, some commonalities were identified. Most striking was the failure to diagnose and report TB patients to a national registry making finding the missing patients a priority for TB control globally. The analysis also found that optimal use of existing tools will not accelerate the rate of decline in TB incidence sufficiently, necessitating the development of new and improved tools for TB control. Finally, it was recognized that gaps in our understanding of TB pathogenesis and protective immunity as well as limited knowledge about the host pathogen interactions in granulomas of infected tissues, hinder the progress needed to develop the new tools for improved TB control. A commitment of all governments to support research, develop new tools such as new diagnostics, better drug regimens and efficacious vaccines, and improving service delivery by TB control programs will be needed to accelerate the reduction in incidence and reduce disease burden globally.
Keywords: Global epidemic; Multidrug resistant tuberculosis; Patient pathway analysis; Tuberculosis; Tuberculosis control.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Improving diagnosis and case management of patients with tuberculosis: A review of gaps, needs and potential solutions in accessing laboratory diagnostics.Infect Genet Evol. 2019 Aug;72:131-140. doi: 10.1016/j.meegid.2018.08.030. Epub 2018 Oct 13. Infect Genet Evol. 2019. PMID: 30326281 Review.
-
Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force.MMWR Recomm Rep. 2009 Feb 13;58(RR-3):1-43. MMWR Recomm Rep. 2009. PMID: 19214162
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Tuberculosis: a new vision for the 21st century.Kekkaku. 2009 Nov;84(11):721-6. Kekkaku. 2009. PMID: 19999594
-
How research can help control tuberculosis.Int J Tuberc Lung Dis. 2009 May;13(5):558-68. Int J Tuberc Lung Dis. 2009. PMID: 19383187 Review.
Cited by
-
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832.Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0058321. doi: 10.1128/AAC.00583-21. Epub 2021 Aug 9. Antimicrob Agents Chemother. 2021. PMID: 34370580 Free PMC article.
-
One Size Fits All? Not in In Vivo Modeling of Tuberculosis Chemotherapeutics.Front Cell Infect Microbiol. 2021 Mar 16;11:613149. doi: 10.3389/fcimb.2021.613149. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 33796474 Free PMC article. Review.
-
Recombinant Human Lactoferrin Reduces Inflammation and Increases Fluoroquinolone Penetration to Primary Granulomas During Mycobacterial Infection of C57Bl/6 Mice.Arch Immunol Ther Exp (Warsz). 2022 Feb 28;70(1):9. doi: 10.1007/s00005-022-00648-7. Arch Immunol Ther Exp (Warsz). 2022. PMID: 35226195 Free PMC article.
-
Assessing the spatial heterogeneity of tuberculosis in a population with internal migration in China: a retrospective population-based study.Front Public Health. 2023 May 30;11:1155146. doi: 10.3389/fpubh.2023.1155146. eCollection 2023. Front Public Health. 2023. PMID: 37325311 Free PMC article.
-
Capture and visualization of live Mycobacterium tuberculosis bacilli from tuberculosis patient bioaerosols.PLoS Pathog. 2021 Feb 1;17(2):e1009262. doi: 10.1371/journal.ppat.1009262. eCollection 2021 Feb. PLoS Pathog. 2021. PMID: 33524021 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical